This is repository of my old source code which isn't updated any more. Go to git.rot13.org for current projects!
ViewVC logotype

Annotation of /news/10.html

Parent Directory Parent Directory | Revision Log Revision Log

Revision - (hide annotations) (vendor branch)
Mon Feb 12 08:22:24 2001 UTC (20 years, 2 months ago) by dpavlin
Branch: MAIN, dbp
CVS Tags: alpha, HEAD
Changes since 1.1: +0 -0 lines
File MIME type: text/html

1 dpavlin 1.1 <p><b>PLIVA and The Althexis Company Announce a Collaboration on the Structure-Based
2     Drug Design of Novel Broad Spectrum Antibiotics</b></p>
3     <p>Zagreb, 8th February 1999</p>
4     <p>PLIVA d.d., Zagreb, Croatia and The Althexis Company, Inc., Boston, MA., USA,
5     today announced that they have entered into a collaboration to develop and commercialise
6     novel broad spectrum antibiotics using structure-based drug design ("SBDD")
7     technologies. PLIVA support for the Althexis program may total $14.4 million
8     over three years in research funding and milestone payments. Additional future
9     revenues to Althexis and PLIVA may result from certain exclusive marketing rights
10     each retains under the collaboration agreement.</p>
11     <p>Under terms of the agreement, PLIVA receives worldwide rights to market any
12     drugs which result from two specified research projects defined in the agreement,
13     except for the countries of Japan, South Korea, and Taiwan, where Althexis reserves
14     those rights. The partners will each retain non-exclusive rights in China.</p>
15     <p>Althexis and PLIVA will apply their expertise in the areas of structural biology,
16     biophysics, biochemistry and chemistry, and in chemistry, microbiology and drug
17     development, respectively, to two antibacterial targets. The companies will
18     pool and share their data, including pre-clinical and clinical results, in support
19     of activities in their respective geographical territories.</p>
20     <p>"We are thrilled to have PLIVA as a partner in our structure-based antibiotics
21     design program", stated Manuel Navia, Ph.D., a co-founder and President of The
22     Althexis Company. "The last twenty years of antimicrobial research have seen
23     a decline in the introduction of new antibacterials and a disturbing increase
24     in the resistance to existing antibiotics. There is a pressing need to broaden
25     the arsenal of antibacterial agents beyond those currently in use. Our collaboration
26     agreement with PLIVA gives Althexis the financial and scientific support it
27     needs to move forward against its initial bacterial targets" concluded Dr. Navia.</p>
28     <p>"Our two organisations fit together very well", said Patrick Connelly, Ph.D.,
29     a co-founder and Chief Scientific Officer of Althexis. "Our expertise in SBDD
30     nicely complements the vigorous program of drug discovery and development that
31     already thrives at PLIVA. The excitement generated during our initial scientific
32     discussions was palpable. Althexis has put together an impressive group of pharmaceutical
33     industry veterans, as well as University and industry based joint ventures,
34     to conduct its research projects. Now we can proceed expeditiously to begin
35     work on the PLIVA-sponsored projects that we are so optimistic about" concluded
36     Dr. Connelly.</p>
37     <p>"PLIVA has a long and distinguished history of truly innovative research, dating
38     back to the founding of the PLIVA Research Institute by Vladimir Prelog, 1975
39     Nobel Laureate in Chemistry. PLIVA's achievements include the discovery, development,
40     and manufacture of azithromycin, the outstanding macrolide antibiotic marketed
41     by Pfizer and PLIVA. We are confident that this partnership can meet the very
42     ambitious development and commercialisation goals we have set and, ultimately,
43     contribute to PLIVA's pipeline of novel anti-infective agents", Zeljko Covic,
44     CEO of PLIVA stated.</p>
45     <p>"We are extremely pleased to collaborate with The Althexis Company. PLIVA believes
46     in the power of SBDD, and Althexis' expertise in this area provides us with
47     a terrific complement to the antibiotics discovery program at PLIVA. This is
48     a powerful collaboration and represents a unique opportunity for PLIVA to explore
49     a state-of-the-art approach to making drugs" stated Radan Spaventi, M.D., Director
50     of the Research Institute at PLIVA.</p>
51     <p>PLIVA is the biggest pharmaceutical company in the area of Central and Eastern
52     Europe and has been listed on the London Stock Exchange since 1996. In 1997,
53     PLIVA acquired a majority stake in one of the biggest Polish pharmaceutical
54     companies, today known as "PLIVA Krakow". PLIVA's current operations consist
55     of research, the development, manufacture, and sale of pharmaceutical, animal
56     health and veterinary, food, and cosmetics products. It is a company with a
57     strong focus on the research and development of new chemical entities. PLIVA's
58     biggest success to date has been the invention, development, and production
59     of azithromycin, which was licensed to Pfizer for worldwide marketing except
60     in countries where PLIVA has retained rights. Azithromycin (Zithromax, Sumamed)
61     posted sales of $1 billion (US) in 1998. Several joint ventures with international
62     pharmaceutical and biotechnology companies, as well as various scientific organisations,
63     together with a significant reshaping of its internal research activities support
64     PLIVA's commercial and strategic goals of becoming an internationally recognised
65     research-driven pharmaceuticals company.</p>
66     <p>The Althexis Company, based in Boston, was founded in 1998 by Drs. Manuel Navia
67     and Patrick Connelly, Paul J. Mass of Mass Ventures LLC (Atlanta, GA) and Michael
68     Dailey of Dailey & Partners (Southport, CT). The Althexis Company is dedicated
69     to discovering novel small molecule drugs to treat diseases in humans. Althexis
70     is committed to the practice of SBDD, a revolutionary approach to drug discovery
71     and development that allows a smaller, more modestly capitalised company to
72     compete effectively with even the largest players in the pharmaceutical industry.
73     The scientific founders of Althexis have been pioneers in the establishment
74     and evolution of SBDD as a scientific and commercial success.</p>

  ViewVC Help
Powered by ViewVC 1.1.26